FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149446514> ?p ?o ?g. }

• W2149446514 endingPage "6124" @default.
• W2149446514 startingPage "6113" @default.
• W2149446514 abstract "The recent RV144 clinical trial showed that an ALVAC/AIDSVAX prime-boost HIV vaccine regimen may confer partial immunity in recipients and reduce transmission by 31%. Trial data suggest that efficacy may initially exceed 70% but decline over the following 3.5 years. Estimating the potential health benefits associated with a one-time vaccination campaign, as well as the projected benefits of repeat booster vaccination, may inform future HIV vaccine research and licensing decisions.We developed a mathematical model to project the future course of the HIV epidemic in the United States under varying HIV vaccine scenarios. The model accounts for disease progression, infection transmission, antiretroviral therapy, and HIV-related morbidity and mortality. We projected HIV prevalence and incidence over time in multiple risk groups, and we estimated quality-adjusted life years (QALYs) and costs over a 10-year time horizon. We assumed an exponentially declining efficacy curve fit to trial data, and that subsequent vaccine boosters confer similar immunity. Variations in vaccine parameters were examined in sensitivity analysis.Under existing HIV prevention and treatment efforts, an estimated 590,000 HIV infections occur over 10 years. One-time vaccination achieving 60% coverage of adults could prevent 9.8% of projected new infections over 10 years (and prevent 34% of new infections in the first year) and cost approximately $91,000/QALY gained relative to the status quo, assuming $500 per vaccination series. Targeted vaccination strategies result in net cost savings for vaccines costing less than $750. One-time vaccination of 60% of all adults coupled with three-year boosters only for men who have sex with men and people who inject drugs could prevent 21% of infections for $81,000/QALY gained relative to vaccination of higher risk sub-populations only. A program attaining 90% vaccination coverage prevents 15% of new HIV cases over 10 years (and approximately 50% of infections in the first year).A partially effective HIV vaccine with effectiveness similar to that observed in the RV144 trial would provide large health benefits in the United States and could meet conventionally accepted cost-effectiveness thresholds. Strategies that prioritize key populations are most efficient, but broader strategies provide greater total population health benefit." @default.
• W2149446514 created "2016-06-24" @default.
• W2149446514 creator A5030796795 @default.
• W2149446514 creator A5049344532 @default.
• W2149446514 date "2011-08-01" @default.
• W2149446514 modified "2023-09-27" @default.
• W2149446514 title "The cost-effectiveness of a modestly effective HIV vaccine in the United States" @default.
• W2149446514 cites W1598895376 @default.
• W2149446514 cites W1970293301 @default.
• W2149446514 cites W1971965350 @default.
• W2149446514 cites W1972227985 @default.
• W2149446514 cites W1974877279 @default.
• W2149446514 cites W1976142347 @default.
• W2149446514 cites W1978999207 @default.
• W2149446514 cites W1979284521 @default.
• W2149446514 cites W1985544232 @default.
• W2149446514 cites W1987136336 @default.
• W2149446514 cites W1987641348 @default.
• W2149446514 cites W1991197870 @default.
• W2149446514 cites W1991563892 @default.
• W2149446514 cites W1992566288 @default.
• W2149446514 cites W2000182266 @default.
• W2149446514 cites W2007914086 @default.
• W2149446514 cites W2017736583 @default.
• W2149446514 cites W2021402216 @default.
• W2149446514 cites W2021484232 @default.
• W2149446514 cites W2023155600 @default.
• W2149446514 cites W2024888854 @default.
• W2149446514 cites W2028706055 @default.
• W2149446514 cites W2035178446 @default.
• W2149446514 cites W2036540047 @default.
• W2149446514 cites W2039617800 @default.
• W2149446514 cites W2041542511 @default.
• W2149446514 cites W2047319295 @default.
• W2149446514 cites W2052263121 @default.
• W2149446514 cites W2053369339 @default.
• W2149446514 cites W2055467237 @default.
• W2149446514 cites W2056291848 @default.
• W2149446514 cites W2056779298 @default.
• W2149446514 cites W2057504223 @default.
• W2149446514 cites W2060057531 @default.
• W2149446514 cites W2060744926 @default.
• W2149446514 cites W2064805032 @default.
• W2149446514 cites W2090669065 @default.
• W2149446514 cites W2099092500 @default.
• W2149446514 cites W2100424501 @default.
• W2149446514 cites W2111047052 @default.
• W2149446514 cites W2111888273 @default.
• W2149446514 cites W2115373328 @default.
• W2149446514 cites W2119019497 @default.
• W2149446514 cites W2121729194 @default.
• W2149446514 cites W2129101850 @default.
• W2149446514 cites W2132957985 @default.
• W2149446514 cites W2135151522 @default.
• W2149446514 cites W2140789060 @default.
• W2149446514 cites W2151969385 @default.
• W2149446514 cites W2152048324 @default.
• W2149446514 cites W2153335467 @default.
• W2149446514 cites W2155075222 @default.
• W2149446514 cites W2159942307 @default.
• W2149446514 cites W2160226661 @default.
• W2149446514 cites W2163036286 @default.
• W2149446514 cites W2166157401 @default.
• W2149446514 cites W2167625271 @default.
• W2149446514 cites W2171141994 @default.
• W2149446514 cites W2171966089 @default.
• W2149446514 cites W2303937306 @default.
• W2149446514 cites W2314461521 @default.
• W2149446514 cites W2315102553 @default.
• W2149446514 cites W2561704609 @default.
• W2149446514 cites W4230038602 @default.
• W2149446514 cites W4238913538 @default.
• W2149446514 cites W4252616118 @default.
• W2149446514 cites W4300423670 @default.
• W2149446514 doi "https://doi.org/10.1016/j.vaccine.2011.04.013" @default.
• W2149446514 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3156325" @default.
• W2149446514 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21510996" @default.
• W2149446514 hasPublicationYear "2011" @default.
• W2149446514 type Work @default.
• W2149446514 sameAs 2149446514 @default.
• W2149446514 citedByCount "26" @default.
• W2149446514 countsByYear W21494465142012 @default.
• W2149446514 countsByYear W21494465142013 @default.
• W2149446514 countsByYear W21494465142014 @default.
• W2149446514 countsByYear W21494465142015 @default.
• W2149446514 countsByYear W21494465142016 @default.
• W2149446514 countsByYear W21494465142017 @default.
• W2149446514 countsByYear W21494465142018 @default.
• W2149446514 countsByYear W21494465142019 @default.
• W2149446514 countsByYear W21494465142020 @default.
• W2149446514 countsByYear W21494465142021 @default.
• W2149446514 countsByYear W21494465142022 @default.
• W2149446514 countsByYear W21494465142023 @default.
• W2149446514 crossrefType "journal-article" @default.
• W2149446514 hasAuthorship W2149446514A5030796795 @default.
• W2149446514 hasAuthorship W2149446514A5049344532 @default.
• W2149446514 hasBestOaLocation W21494465142 @default.
• W2149446514 hasConcept C112930515 @default.

• next